Inhibition of KRAS(G12D) mutant cell lines The promising results for the inhibitory activity and mutant-selectivity from the ITC and KRAS–CRAF interaction assays motivated us to evaluate the potential anti-cancer effects of TH-Z827. The KRAS G12D mutation is the most prevalent mutation form ...
这就要求,一方面需要创新,开发新型的、高效、广谱的KRAS抑制剂,(而不仅仅作为一个搅局者,为了卷而卷);另一方面需要研究KRASG12D不同抑制剂的作用机制,以及联合用药的可能,和开发,更好的服务于疾病的治疗。 参考文献: 1)A Small Molecule with Big Impact: MRTX1133 ...
G12D point mutation negatively correlated with PD-L1 level and secretion of chemokines CXCL10/CXCL11 that led to a decrease in CD8+TILs,which in turn yielded an immunosuppressive TIME.The analysis of cell lines overexpressing classic KRAS substitutions further revealed that KRAS-G12D mutation ...
Tregs)高比例浸润密切相关,KRASG12D 突变通过激活下游的 MEK/ERK 通路,促进 ERK 磷酸化,造成白细胞介素 10(interleukin-10,IL-10)和转化生长因子-β(TGF-β)的过表达,使得 Tregs 大量富集,最终导致胰腺癌组织产生免疫抑制。
货号:ABC-KH8069 价格:¥询价 规格: 1 vial 数量:-+ 产品描述 参考文献 资料下载 相关产品 产品描述/Products Description Human KRAS (G12D/+) LIM1215 Cell lineis Heterozygous knockin of KRAS activating mutation (G12D). 资料下载 相关产品
目前，针对KRAS G12C靶点的研究方兴未艾，而对KRAS G12D等其他靶点的探索以及泛RAS抑制剂的研发也已进入临床开发阶段。MRTX1133是Mirati Therapeutics研发的一款选择性非共价 KRAS G12D 抑制剂，目前已经获得了FDA 批准，获得新药临床试验申请批准，在 2023 年已经开始进入 I/II 期临床阶段。临床前研究结果显示：...
化合物 KRAS G12D MUTATION REGULATOR 4 CAS号: 2621927-57-7 英文名: 2-Naphthalenol, 4-[4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-8-fluoro-2-[(tetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl- ...
KRAS mutations are among the most prevalent oncogenic alterations in cancer patients, with the G12D mutation being one of the most challenging to target effectively. Despite significant advances in cancer research and therapy, KRAS-driven cancers present a substantial unmet medical need, underscoring ...
在非小细胞肺癌、结直肠癌、胰腺癌、胃癌,以及胆道肿瘤等肿瘤中均存在KRAS G12C突变,但是占比较低。如果能针对KRAS突变进行治疗,则很多类型的肿瘤患者都有可能获得更好的治疗效果。以前认为KRAS不能成药,经过大家多年的努力,终于能在...
1: Case report: Successful treatment of advanced pulmonary sarcomatoid carcinoma with BUBIB-ALK rearrangement and KRAS G12C mutation by sintilimab combined with anlotinib.. Front Oncol. 2024 Feb 13;14:1269148. doi: 10.3389/...